Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
Eledon Pharmaceuticals (NASDAQ:ELDN) announced it will host an R&D Day on July 9, 2025 in New York City, starting at 8:30 am ET. The event will showcase the company's lead investigational candidate, tegoprubart, focusing on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial.
The R&D Day will feature presentations from Eledon's executive team and leading transplantation experts from prestigious institutions. Topics will cover unmet needs in solid organ transplantation, clinical endpoint evolution, and strategic opportunities in islet cell transplantation and xenotransplantation. The event will conclude with a Q&A session and will be available via live webcast.
Eledon Pharmaceuticals (NASDAQ:ELDN) ha annunciato che terrà un R&D Day il 9 luglio 2025 a New York, con inizio alle 8:30 ET. L'evento presenterà il candidato principale dell'azienda, tegoprubart, concentrandosi sul suo sviluppo clinico nel trapianto di organi e cellule, incluso il trial di Fase 2 BESTOW attualmente in corso.
Durante l'R&D Day, il team esecutivo di Eledon e rinomati esperti di trapianto provenienti da istituzioni prestigiose terranno presentazioni. Gli argomenti tratteranno le necessità non soddisfatte nel trapianto di organi solidi, l'evoluzione degli endpoint clinici e le opportunità strategiche nel trapianto di cellule insulari e nella xenotrapianto. L'evento si concluderà con una sessione di domande e risposte e sarà trasmesso in diretta via webcast.
Eledon Pharmaceuticals (NASDAQ:ELDN) anunció que realizará un Día de I+D el 9 de julio de 2025 en la ciudad de Nueva York, comenzando a las 8:30 am ET. El evento mostrará el candidato principal de la compañía, tegoprubart, centrado en su desarrollo clínico en trasplantes de órganos y células, incluyendo el ensayo de Fase 2 BESTOW en curso.
El Día de I+D contará con presentaciones del equipo ejecutivo de Eledon y de destacados expertos en trasplantes de instituciones prestigiosas. Los temas abordarán las necesidades no cubiertas en el trasplante de órganos sólidos, la evolución de los endpoints clínicos y las oportunidades estratégicas en el trasplante de células de islotes y xenotrasplantes. El evento concluirá con una sesión de preguntas y respuestas y estará disponible vía webcast en vivo.
Eledon Pharmaceuticals (NASDAQ:ELDN)는 2025년 7월 9일 오전 8시 30분(동부시간)부터 뉴욕시에서 연구개발(R&D) 데이를 개최한다고 발표했습니다. 이번 행사에서는 회사의 주요 임상 후보물질인 tegoprubart를 소개하며, 장기 및 세포 이식 분야의 임상 개발, 특히 진행 중인 2상 BESTOW 임상시험에 중점을 둘 예정입니다.
R&D 데이에는 Eledon의 경영진과 명망 있는 기관의 이식 분야 전문가들이 발표를 진행합니다. 발표 주제는 고형 장기 이식의 미충족 수요, 임상 평가 기준의 변화, 그리고 이자세포 이식 및 이종 이식 분야의 전략적 기회를 다룰 것입니다. 행사는 질의응답 세션으로 마무리되며, 생중계 웹캐스트를 통해 시청할 수 있습니다.
Eledon Pharmaceuticals (NASDAQ:ELDN) a annoncé qu’elle organisera une journée R&D le 9 juillet 2025 à New York, à partir de 8h30 ET. L’événement mettra en lumière le principal candidat en investigation de la société, tegoprubart, en se concentrant sur son développement clinique dans la transplantation d’organes et de cellules, y compris l’essai Phase 2 BESTOW en cours.
La journée R&D comprendra des présentations de l’équipe de direction d’Eledon ainsi que des experts renommés en transplantation issus d’institutions prestigieuses. Les sujets aborderont les besoins non satisfaits dans la transplantation d’organes solides, l’évolution des critères cliniques, ainsi que les opportunités stratégiques dans la transplantation de cellules des îlots et la xénotransplantation. L’événement se terminera par une session de questions-réponses et sera diffusé en direct par webcast.
Eledon Pharmaceuticals (NASDAQ:ELDN) gab bekannt, dass es am 9. Juli 2025 in New York City einen R&D-Tag veranstalten wird, der um 8:30 Uhr ET beginnt. Die Veranstaltung wird den führenden klinischen Kandidaten des Unternehmens, tegoprubart, vorstellen und sich auf dessen klinische Entwicklung im Bereich Organ- und Zelltransplantation konzentrieren, einschließlich der laufenden Phase-2 BESTOW-Studie.
Der R&D-Tag beinhaltet Präsentationen des Eledon-Managementteams sowie von führenden Transplantationsexperten renommierter Institutionen. Die Themen umfassen ungedeckte Bedürfnisse bei der Transplantation solider Organe, die Entwicklung klinischer Endpunkte sowie strategische Chancen bei Inselzelltransplantationen und Xenotransplantationen. Die Veranstaltung endet mit einer Fragerunde und wird per Live-Webcast übertragen.
- None.
- None.
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am ET.
The event will feature members of Eledon’s executive team and the following leading experts in transplantation:
- Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
- John D. Cleveland, M.D., Associate Professor of Clinical Surgery, Program Director, Congenital Cardiac Surgery Fellowship, Children’s Hospital Los Angeles, Department of Surgery, Keck School of Medicine
- William E. Fitzsimmons, Pharm.D., M.S., Adjunct Professor, University of Illinois Colleges of Medicine and Pharmacy; Executive Committee, Transplant Therapeutics Consortium
- Piotr Witkowski, M.D., Ph.D., Professor of Surgery and Director of the Pancreatic and Islet Transplant Program at UChicago Medicine
The R&D Day event will highlight Eledon’s lead investigational candidate, tegoprubart, with a focus on its clinical development in organ and cell transplantation, including the ongoing Phase 2 BESTOW trial. Additional sessions will address unmet needs in solid organ transplantation, the evolution of clinical endpoints such as iBox and eGFR, and the Company’s strategic opportunities in islet cell transplantation and xenotransplantation. The program will conclude with a live Q&A session featuring Eledon’s management team and invited key opinion leaders.
To register for the in-person event, please email: claire.mccardell@gilmartinir.com. A live webcast of the event and presentation materials will be available on the “Events” section of Eledon’s website at www.eledon.com.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When and where is Eledon Pharmaceuticals (ELDN) hosting its R&D Day 2025?
What topics will be covered at Eledon's (ELDN) R&D Day 2025?
Who are the key speakers at Eledon's (ELDN) R&D Day 2025?
How can investors attend or access Eledon's (ELDN) R&D Day 2025?
